Lenalidomid 123-Acurae Pharma (Lenalidomide)

Lenalidomide works by enhancing the activity of T‑cells and natural killer cells, suppressing the formation of new blood vessels that feed tumors, and directly inhibiting tumor cell growth. It modifies cytokine production and promotes the degradation of transcription factors that malignant cells rely on, leading to reduced proliferation.

The specific dose of Lenalidomid 123-Acurae Pharma is determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and overall health. Healthcare providers tailor the regimen to achieve optimal therapeutic benefit while minimizing risks.

Lenalidomid 123-Acurae Pharma is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended while receiving the medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens to enhance immune response and inhibit angiogenesis, providing an alternative or complementary option to other standard therapies.

Store Lenalidomid 123-Acurae Pharma at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain product stability throughout its shelf life.

The medication is taken orally, usually once daily, with or without food as directed by the prescriber. Patients should swallow the tablet whole and follow any specific timing or dietary instructions provided by their healthcare professional.

Serious risks include venous thromboembolism, severe neutropenia or thrombocytopenia leading to infection or bleeding, secondary primary malignancies, and profound teratogenic effects. Patients should be monitored closely for these events, and immediate medical attention is required if they occur.

Lenalidomid 123-Acurae Pharma should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled severe infections. Caution is also advised for those with significant renal impairment or a history of thromboembolic events.